If the Secretary designates a drug under section 355f(d) of this title as a qualified infectious disease product, then the Secretary shall give priority review to any application submitted for approval for such drug under section 355(b) of this title.
(June 25, 1938, ch. 675, §524A, as added Pub. L. 112–144, title VIII, §802(a), July 9, 2012, 126 Stat. 1079.)
Sections: Previous 360h-1 360i 360j 360k 360l 360m 360n 360n-1 360aa 360bb 360cc 360dd 360ee 360ff 360hh Next
Last modified: October 26, 2015